The Melanoma Research Alliance (MRA) stands as the largest non-profit funder of melanoma research. Founded in 2007 by Debra and Leon Black, MRA's mission is to end suffering and death due to melanoma by advancing the world's most promising science and research. MRA provides critical funding for melanoma cancer research that propels advances in prevention, diagnosis, treatment, metastasis, and survivorship. MRA-funded researchers have been behind every major melanoma research breakthrough. Since MRA's inception, more than 15 new therapeutic approaches for melanoma have earned FDA approval. MRA is recognized as one of the most fiscally efficient non-profits in the country. Because MRA's Founders generously cover 100% of MRA's administrative and operating costs, every dollar donated is invested directly into MRA's scientific and research program. For more information, please visit: www.CureMelanoma.org.
February 16, 2024
Article
The Food and Drug Administration approved Amtagvi, a TIL therapy, for patients with advanced melanoma whose disease progressed on or after a checkpoint inhibitor and targeted therapy.
October 16, 2023
Article
The FDA approved Opdivo for the treatment of patients aged 12 years and older with stage 2B or 2C melanoma that has been surgically removed
October 10, 2023
Article
A diagnosis of a rare internal form of melanoma left J.B. Ward and her care team in “a whirlwind of confusion,” but she pushed for aggressive forms of treatment.
September 28, 2023
Article
An expert discusses what patients can expect when being treated with the Hepzato kit, a direct-to-liver therapy for metastatic uveal melanoma.
August 11, 2023
Article